慢性失眠中的mPFC-rTMS的影响:一项随机,双盲,安慰剂控制的随机研究
Jingjing Sun1, Panpan Li1, Yun Yi1
1Zhenjiang Mental Health Center, No.199, Tuanshan Road, Zhenjiang, Jiangsu, 212001, China.
Sleep medicine
|August 7, 2025
概括
针对中部前额叶皮层 (mPFC) 的重复性横磁刺激 (rTMS) 在试点研究中显著改善了慢性失眠症状. 该疗法显示出良好的安全性,这表明它有可能成为一种有效的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 睡眠医学 睡眠医学
- 精神病学是一个精神病学.
背景情况:
- 中间前额叶皮层 (mPFC) 与失眠的病理生理学有关.
- mPFC刺激为失眠治疗提供了潜在的治疗点.
研究的目的:
- 评估重复性跨磁刺激 (rTMS) 对慢性失眠的疗效和安全性.
- 调查rTMS对失眠严重程度和相关症状的影响.
主要方法:
- 进行了一项试点,双盲,随机,假控制试验.
- 患有慢性失眠的62名参与者接受了针对mPFC的20次会议的活跃或虚拟rTMS.
- 评估是在基线,干预结束和4周后续进行的.
主要成果:
- 活跃的rTMS组在干预后显示出明显更高的响应和缓解率,与虚假组相比 (p=0.037和p=0.048).
- 积极的rTMS导致失眠严重程度 (PSQI得分),睡眠开始延迟,每日干扰和随访时减少催眠药物的使用显著改善.
- 两组之间没有观察到不良事件的显著差异,没有报告严重不良事件.
结论:
- 针对mPFC的rTMS显示出作为慢性失眠的有效和安全治疗干预的潜力.
- 这些发现支持对用于治疗失眠的rTMS的进一步调查.
相关概念视频
Management of Insomnia
322
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
322
Sedatives and Hypnotics Drugs: Miscellaneous Agents
243
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
243
Insomnia
125
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
125


